Although SGLT2 inhibitors have been proven to have cardiovascular protective effects, and the incidence of major adverse cardiovascular events, cardiovascular mortality, heart failure, and all-cause mortality observed under SGLT2i treatment have all been reduced, non-fatal strokes unexpectedly increased by 30% (27). This evidence concerns the gene SLC5A2 and heart failure.